ClinicalTrials.gg
CompletedNCT05170763Updated Jan 19, 2022

Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

A Phase 1 interventional study of PA9159 nasal spray solution, 10 μg one day treatment and PA9159 nasal spray solution, 20 μg one day treatment in Allergic Rhinitis, sponsored by Anhui Palo Alto Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by Anhui Palo Alto Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.

Enrollment
45th of 67
60 · median 93
Started
2021
with 3 others
Phase 1
8 of 82
1 open now
Registered
26th of 82
by date
Lead sponsor
3 of 82
Anhui Palo Alto Pharmaceuticals, Inc.

Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 45th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2021, is one of 8 in phase 1, and was the 26th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Rhinitis, Allergic with a site in China, or all of them as a file.
02

Study summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult

Read the detailed description

This is a randomized, double-blind, placebo-controlled dose escalation phase 1 trial, including single dose and 7-day repeat doses of PA9159 nasal spray. In the first part of the study, the treatment is given once for one day, with escalation doses of 10 μg, 20 μg, 40 μg, 80 μg. In the second part of the study, PA9159 at the escalation dose of 20 μg and 40 μg is given once a day for 7 days. 10 health subjects will be enrolled for each dose group, randomized proportionally at 4:1 ratio to receive either the investigational product PA9159 or placebo nasal spray, with a total of 60 subjects for this two-part study. Subjects will be evaluated for the safety, tolerability and pharmacokinetics of PA9159 intranasal spray.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 to 65 years (including upper and lower limits);
  • Male body weight ≥ 50 kg, female weight ≥ 45 kg, (BMI) between 19 and 28 kg/m2 (including cut-off values);
  • Voluntary participation and signing of .

Exclusion criteria

Exclusion Criteria:

  • Those with a history or current history of serious diseases such as respiratory, cardiovascular, digestive, endocrine, hematological, immune, psychiatric, neurological, and otologic diseases, with special attention to a history of recurrent (defined as > 1) or disseminated herpes zoster, history of recurrent infections, tuberculosis infection, glaucoma and cataract; Suffering from acute, chronic or local infectious diseases (e.g., eye, nose infection, etc.);
  • Those who are allergic to the study drug or any component of the study drug (refer to the susceptibility of the body to allergic reactions, or to a variety of food, drugs, or environmental substances);
  • Any past or current medical history that may affect the safety of the study in the body, especially any nasal disorder affecting drug absorption: a) History of long-term nasal congestion, rhinorrhea, nasal pruritus, headache, epistaxis, etc.; b) asthma, aspirin stress response, chronic respiratory disease, etc.; c) History of nasal surgery, trauma, allergic rhinitis, chronic rhinitis, sinusitis, severe deviation of nasal septum, etc., and the researchers believe that it is still ;
  • Abnormal and clinically significant vital signs, physical examination, nasal examination, laboratory tests (hematology, blood chemistry, urinalysis, coagulation function, serum cortisol), , etc., during screening;
  • Positive test results and have clinical significance for HIV-P24 antigen/antibody, virus (HCV) antibody, treponema pallidum (TP), or five items (hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B e antigen, hepatitis B e antibody, and hepatitis B core antibody);
  • Regular drinkers within 6 months prior to screening,That is, drink more than 14 units of alcohol per week (1 unit = 360 mL of beer containing 5% alcohol or 45 mL of spirits with 40% alcohol or 150 mL of wine with 12% alcohol content) or who have a positive alcohol breath test at screening or who cannot stop alcohol intake during the study;
  • Smoking more than 5 cigarettes per day on average within 3 months prior to screening, or unable to discontinue the use of any tobacco products during the trial;
  • History of drug abuse, history of drug abuse, or positive urine screening for drug abuse (including morphine, methamphetamine, ketamine, dimethyldioxymethamphetamine, tetrahydrocannabinol acid);
  • Those who have taken any drugs (prescription drugs, over-the-counter drugs, Chinese herbal medicines, vaccines) or health products within 2 weeks prior to screening and during screening;
  • Those who have used -containing preparations or any drugs that affect enzyme activity (e.g., ritonavir or ketoconazole, etc.) within 30 days prior to screening and during screening;
  • Consumption of beverages or foods containing grapefruit, dragon fruit, mango, grapefruit, pomegranate, papaya, carambola within 14 days prior to screening and during screening, or who do not agree to stop eating the above-mentioned diet during the study;
  • Consumption of any caffeine- and xanthine-rich food or beverages (coffee, tea, cola, chocolate, seafood, animal liver, etc.) within 48 hours prior to the first dose of study drug, or who do not agree to stop eating these diets during the study;
  • It cannot be guaranteed that effective measures or fertility planners or sperm or egg donors are taken during the trial and for at least 1 year after the last dose;
  • Donation or massive blood loss (≥ 300 mL, except during female physiology) or use of blood products or transfusions within 90 days prior to screening and during screening;
  • Participating in other clinical investigators or subjects participating in other clinical trials within 90 days prior to screening for less than 7 days;
  • Major surgery (as judged by the investigator based on past medical history data), major trauma, or planned surgery during the study within 6 months prior to screening;
  • Difficulty in venous blood collection, or a known history of multiple needle sickness and blood sickness;
  • Women with a positive pregnancy test or breastfeeding;
  • Other conditions that, in the opinion of the investigator, are not suitable for participation in the study or the subject is unable to participate in the study due to his/her own reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    PA9159 10 μg single dose and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 10 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 10 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 20 μg single dose and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 20 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 20 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 40 μg single dose and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 40 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 40 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 80 μg single dose and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data.

    Drug: PA9159 nasal spray solution, 80 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 20 μg repeated doses and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 20 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 20 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 40 μg repeated doses and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 40 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data.

    Drug: PA9159 nasal spray solution, 40 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects experiencing adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.

    Time frame: up to 7 days after last nasal spray treatment

  2. Number of subjects having abnormal hematology laboratory parameters

    Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

    Time frame: within 24 hours after last nasal spray treatment

  3. Number of subjects with abnormal clinical chemistry parameters

    Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

    Time frame: within 24 hours after last nasal spray treatment

  4. Number of subjects with abnormal values for urinalysis

    Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

    Time frame: within 24 hours after last nasal spray treatment

  5. Body temperature

    Vital sign-Body temperature

    Time frame: up to 24 hours after last nasal spray treatment

  6. Systolic and diastolic blood pressure

    Vital sign-Systolic and diastolic blood pressure

    Time frame: up to 24 hours after last nasal spray treatment

  7. Pulse rate

    Vital sign-Pulse rate

    Time frame: up to 24 hours after last nasal spray treatment

  8. ECG parameter-QTc interval

    A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically calculates the QTc intervals

    Time frame: up to 24 hours after last nasal spray treatment

  9. ECG parameter-PR interval

    A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR intervals

    Time frame: up to 24 hours after last nasal spray treatment

  10. ECG parameter-QRS duration

    A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration

    Time frame: up to 24 hours after last nasal spray treatment

  11. Numbers of subjects experiencing local nasal/throat irritation symptoms

    Self reported local irritation symptoms including pruritus, dryness, sneezing, nasal congestion, rhinorrhea, dry cough and odynophagia

    Time frame: up to 24 hours after nasal spray treatment

  12. Numbers of subjects showing signs of local reactions

    Visual nasal examination will be conducted by a trained physician for presence of nasal cavity erythema, edema, epistaxis, perforation of the nasal septum, or any abnormal finding deemed clinically significant.

    Time frame: up to 24 hours after nasal spray treatment

Secondary outcomes

  1. Serum cortisol levels

    Monitor the concentration changes of serum cortisol before and after PA9159 administration.

    Time frame: From pre-dose until 24 hours post-dose

  2. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-Cmax

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 10, 20, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  3. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-Tmax

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 10, 20, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  4. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-AUC

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 10, 20, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  5. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-T1/2

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Half-Life Period (T1/2)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 10, 20, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

07

Study locations

1 site
  • Beijing TongRen Hospital
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jan 2022, 1 month.

Of 25 phase 1 interventional studies under Rhinitis, Allergic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Dec 28, 2021
StartActual
Nov 10, 2021
Primary completionActual
Jan 5, 2022
CompletionActual
Jan 5, 2022
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05170763
Lead sponsor
Anhui Palo Alto Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 28, 2021
Start date
Nov 10, 2021
Primary completion
Jan 5, 2022
Completion
Jan 5, 2022
Last update
Jan 19, 2022

Study contacts

Luo Zhang
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA9159

Start the discussion